Predictive biomarkers in radioresistant rectal cancer: A systematic review

Crit Rev Oncol Hematol. 2023 Jun:186:103991. doi: 10.1016/j.critrevonc.2023.103991. Epub 2023 Apr 13.

Abstract

Background and aims: The treatment of locally advanced rectal cancer often consists of neoadjuvant chemoradiotherapy followed by surgery. However, approximately 15% of patients show no response to this neoadjuvant chemoradiotherapy. This systematic review aimed to identify biomarkers of innate radioresistant rectal cancer.

Method: Through a systematic literature search, 125 papers were included and analyzed using ROBINS-I, a Cochrane risk of bias tool for non-randomized studies of interventions. Both statistically significant and nonsignificant biomarkers were identified. Biomarkers mentioned more than once in the results or biomarkers with a low or moderate risk of bias were included as the final results.

Results: Thirteen unique biomarkers, three genetic signatures, one specific pathway, and two combinations of two or four biomarkers were identified. In particular, the connection between HMGCS2, COASY, and PI3K-pathway seems promising. Future scientific research should focus on further validating these genetic resistance markers.

Keywords: Molecular biomarker; Neoadjuvant therapy; Radiotherapy; Rectal Neoplasms; Resistance.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Chemoradiotherapy / methods
  • Humans
  • Neoadjuvant Therapy / methods
  • Neoplasm Staging
  • Phosphatidylinositol 3-Kinases*
  • Rectal Neoplasms* / diagnosis
  • Rectal Neoplasms* / radiotherapy
  • Treatment Outcome

Substances

  • Phosphatidylinositol 3-Kinases
  • Biomarkers, Tumor